Shares of vaccine manufacturers, including Moderna and CureVac, rose on Monday amid rising seasonal flu activity in the United States. Moderna securities gained 3.4%, while CureVac rose by 13%. The growth also affected other companies: Novavax shares increased by 3.1%, and BioNTech – by 1.4%. The increased interest in the shares is related to data from the Arkansas Department of Health, where flu activity has reached the «Very high» level – 11 points out of 13. This is the first such reading since the start of the flu season on September 30 and a marked increase from the «High» levels in previous weeks. At the beginning of the month, flu activity was assessed as «Low». Analysts note that the jump in seasonal morbidity will continue to boost demand for shares of vaccine developers, strengthening their position in the market.
